South Africa’s Adcock Ingram gave a sprawling update of its operations for the first half of its financial year ending in June 2022, which saw a rise in sales but a decline in profit for its Prescription business.

South African firm Adcock Ingram has described the launch of Celltrion’s Remsima (infliximab) biosimilar as “a really good step for us,” as it saw volumes plunge for its Prescription business during its financial year ended 30 June.

Adcock has made slight progress despite the effect of the current economic climate in South Africa on consumer spending and behavior.

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced May and June 2014.